Catalyst Pharmaceuticals (CPRX) Payables (2010 - 2026)

Catalyst Pharmaceuticals has reported Payables for 17 years, with the latest figure at $7.2 million in Q1 2026.

• For the quarter ending Q1 2026, Payables fell 36.13% year-over-year to $7.2 million; the trailing twelve-month figure through Mar 2026 stood at $7.2 million (down 36.13% YoY), and the FY2025 full-year result was $11.2 million, down 32.49% from the prior year.
• Payables for Q1 2026 stood at $7.2 million, down from $11.2 million in the prior quarter.
• The five-year high for Payables was $16.6 million in Q4 2024, with the low at $2.3 million in Q2 2022.
• Historically, Payables has averaged $7.7 million across 5 years, with a median of $7.1 million in 2024.
• Annual changes were most pronounced in 2023 — Payables soared 272.2% — and 2026, when it plunged 36.13%.
• Catalyst Pharmaceuticals' Payables stood at $4.0 million in 2022, then soared by 272.2% to $14.8 million in 2023, then advanced by 12.15% to $16.6 million in 2024, then plunged by 32.49% to $11.2 million in 2025, then slumped by 36.16% to $7.2 million in 2026.
• The last three Payables figures came in at $7.2 million (Q1 2026), $11.2 million (Q4 2025), and $9.1 million (Q3 2025), per Business Quant data.